Synonym
JNJ-632; JNJ 632; JNJ632;
IUPAC/Chemical Name
(S)-N-(4-fluoro-3-methylphenyl)-3-(N-(tetrahydrofuran-3-yl)sulfamoyl)benzamide
InChi Key
JIZGLOVJKCSHTH-HNNXBMFYSA-N
InChi Code
InChI=1S/C18H19FN2O4S/c1-12-9-14(5-6-17(12)19)20-18(22)13-3-2-4-16(10-13)26(23,24)21-15-7-8-25-11-15/h2-6,9-10,15,21H,7-8,11H2,1H3,(H,20,22)/t15-/m0/s1
SMILES Code
O=C(NC1=CC=C(F)C(C)=C1)C2=CC=CC(S(=O)(N[C@@H]3COCC3)=O)=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
In vitro activity:
CAM (capsid assembly modulator) JNJ-632 is a novel and potent inhibitor of HBV replication in vitro across genotypes A to D. It induces the formation of morphologically intact viral capsids, as demonstrated by size exclusion chromatography and electron microscopy studies.
Reference: Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00560-17. https://pubmed.ncbi.nlm.nih.gov/28584155/
In vivo activity:
Administration of JNJ-632 in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.
Reference: J Med Chem. 2018 Jul 26;61(14):6247-6260. https://pubmed.ncbi.nlm.nih.gov/29906396/
|
Solvent |
mg/mL |
mM |
| Solubility |
| Ethanol |
76.0 |
200.84 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
378.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00560-17. doi: 10.1128/AAC.00560-17. PMID: 28584155; PMCID: PMC5527576.
2. Vandyck K, Rombouts G, Stoops B, Tahri A, Vos A, Verschueren W, Wu Y, Yang J, Hou F, Huang B, Vergauwen K, Dehertogh P, Berke JM, Raboisson P. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260. doi: 10.1021/acs.jmedchem.8b00654. Epub 2018 Jul 3. PMID: 29906396.
In vitro protocol:
1. Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00560-17. doi: 10.1128/AAC.00560-17. PMID: 28584155; PMCID: PMC5527576.
In vivo protocol:
1. Vandyck K, Rombouts G, Stoops B, Tahri A, Vos A, Verschueren W, Wu Y, Yang J, Hou F, Huang B, Vergauwen K, Dehertogh P, Berke JM, Raboisson P. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260. doi: 10.1021/acs.jmedchem.8b00654. Epub 2018 Jul 3. PMID: 29906396.
1: Vandyck K, Rombouts G, Stoops B, Tahri A, Vos A, Verschueren W, Wu Y, Yang J,
Hou F, Huang B, Vergauwen K, Dehertogh P, Berke JM, Raboisson PJMB. Synthesis and
Evaluation of N-phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly
Modulators inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jun 15. doi:
10.1021/acs.jmedchem.8b00654. [Epub ahead of print] PubMed PMID: 29906396.
2: Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K,
Pauwels F. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary
Human Hepatocytes Infected with Hepatitis B Virus. Antimicrob Agents Chemother.
2017 Jul 25;61(8). pii: e00560-17. doi: 10.1128/AAC.00560-17. Print 2017 Aug.
PubMed PMID: 28584155; PubMed Central PMCID: PMC5527576.
